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Introduction: Malignant pleural mesothelioma (MPM) is a highly 
aggressive neoplasm associated with asbestos exposure. Currently, 
the molecular mechanisms that induce MPM development are still 
unknown. The purpose of this study was to identify new molecular 
biomarkers for mesothelial carcinogenesis.
Methods: We analyzed a panel of 84 genes involved in extracellu-
lar matrix remodeling and cell adhesion by polymerase chain reac-
tion (PCR) array in 15 samples of epithelioid mesothelioma and 
10 samples of reactive mesothelial hyperplasia (MH; 3 of 25 sam-
ples were inadequate for mRNA analysis). To validate the differen-
tially expressed genes identified by PCR array, we analyzed 27 more 
samples by immunohistochemistry, in addition to the 25 samples 
already studied.
Results: Twenty-five genes were differentially expressed in MPM 
and MH by PCR array. Of these we studied matrix metalloprotein-
ase 7 (MMP7), MMP14, CD44, and integrin, alpha3 expression by 
immunohistochemistry in 26 epithelioid MPM and 26 MH samples 
from the entire series of 52 cases. We observed higher MMP14 and 
integrin, alpha3 expression in MPM samples compared with MH 
samples (p = 0.000002 and p = 0.000002, respectively). Conversely, 
CD44 expression was low in most (57.7%) mesothelioma samples 
but only in 11.5% of the MH samples (p = 0.0013). As regards 
MMP7, we did not observe differential expression between MH and 
MPM samples.
Conclusions: We have extensively studied genes involved in cell 
adhesion and extracellular matrix remodeling in MPM and MH sam-
ples, gaining new insight into the pathophysiology of mesothelioma. 
Moreover, our data suggest that these factors could be potential 
b iomarkers for MPM.
Key Words: Mesothelioma, Mesothelial hyperplasia, Mesothelial 
carcinogenesis, Real-time polymerase chain reaction, 
Immunohistochemistry.
(J Thorac Oncol. 2013;8: 1389–1395)
Malignant pleural mesothelioma (MPM) is a highly aggressive and relatively rare tumor associated with 
asbestos exposure and arises in the pleura from mesothelial 
cells. The MPM incidence varies around the world and shows 
different trends in North America compared with that in other 
Western and non-Western countries. It is estimated that the 
disease has already reached its peak incidence in the United 
States, whereas the peaks in Europe, Australia, and Japan are 
predict to occur in the current decade.1 MPM is characterized 
by a rapid progression and invasion of intrathoracic structures, 
and the median survival is now 12 months from the onset of 
symptoms, leaving a poor prognosis for the patient.2 Presently, 
there is no satisfactory treatment for MPM; however, recent 
reports suggest that multimodality therapy may result in a sig-
nificant improvement in the survival of certain patients.3,4
Until now, the molecular mechanisms that induce MPM 
development are still unknown, and few putative biomarkers 
have been clearly defined for this deadly disease. The long 
incubation period of asbestos-related mesothelioma develop-
ment implies that the malignant transformation is related to 
different and multiple genetic changes.5
The separation of benign reactive mesothelial hyper-
plasia (MH) from malignant epithelioid mesothelioma is cru-
cial to patient management; however, for the pathologist, this 
distinction can be exceedingly difficult, and even experts in 
the field frequently cannot come to a consensus on a given 
case.6 Numerous attempts have been made to resolve the prob-
lem of benignity versus malignancy by using immunohisto-
chemical staining.7–10 Although certain immunohistochemical 
stains are more likely to show positivity in MH and others 
in MPM, immunohistochemistry has yet to provide a marker 
that reliably separates benign from malignant mesothelial 
proliferation, and invasion is still the most reliable indicator 
of malignancy.11
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The invasion of malignant tumor cells is a complicated 
process that involves several classes of proteins implicated in 
the destruction of the basement membrane (BM), proteolysis 
of the extracellular matrix (ECM), and in cell adhesion.12
Proteolysis of the ECM and BM is a central part of tumor 
growth and metastasis. The stromal remodeling mediated by 
proteases also facilitates tumor angiogenesis.13 Cell adhesion 
molecules (CAMs) are involved in the adhesion of cells to 
both adjacent cells and the ECM and are responsible for the 
maintenance of a normal tissue phenotype. Many aspects 
of oncogenesis involve changes in CAM expression,which 
are correlated with invasion and progression in several 
neoplasms.14–16
Given these observations and the central role of inva-
sion in mesothelial proliferations, we decided to study pro-
teins involved in tumor invasion, such as ECM proteins and 
CAMs, evaluating their differential expression level in MPM 
and MH to identify new molecular biomarkers of meso-
thelial carcinogenesis. To characterize the mRNA expres-
sion profiles in epithelioid MPM and MH, we analyzed a 
panel of 84 genes simultaneously. We chose the ECM and 
cell adhesion polymerase chain reaction arrays designed 
to determine the gene expression profile of the molecules 
involved in ECM remodeling and cell adhesion, including 
integrins, selectins, collagens, catenins, CAM family mem-
bers, calcium-dependent cadherins, and matrix metallopro-
teinases (MMPs). Differential gene expression identified 
using the real-time polymerase chain reaction (RT-PCR) 
array was further validated by immunohistochemistry on a 
larger series of samples.
PATIENTS AND METHODS
Patients
Twenty-six patients with epithelioid MPM (age range, 
35–83 years; median, 66.5 years), 21 men and five women, 
and 26 patients with MH (age range, 17–87 years; median, 
63 years), 22 men and four women, who consecutively under-
went surgical resection at the Unit of Thoracic Surgery of the 
University of Pisa, Italy, from January 2006 to September 
2012, were retrospectively studied. A subset of 15 epithelioid 
mesothelioma samples and 10 reactive MH samples was ana-
lyzed using RT-PCR arrays, and immunohistochemical analy-
sis was performed on all MPM and MH samples.
All patients with MPM had a pleurectomy/decortica-
tion, and no patient received chemotherapy or radiotherapy 
before surgery. In the cohort of 26 patients, MH was an inci-
dental finding associated with pleural inflammatory effusions 
and bullous emphysemas.
Participation in this study required informed consent. 
Clinical information, including patient sex and age, were 
reviewed for each patient.
Tumor Specimens
All samples were formalin fixed and paraffin embedded 
(FFPE) for microscopic examination. The most representative 
paraffin blocks of mesothelioma and MH were selected for 
molecular and immunohistochemical analyses for each case.
The diagnoses of MPM and MH were reviewed by two 
pathologists (GA and GF) according to the World Health 
Organization 2004 histologic and immunohistochemical cri-
teria.17 Disagreements concerning diagnosis were discussed, 
and after a critical discussion, mutual agreement was reached.
RNA Purification and cDNA Synthesis
After standard deparaffinization, FFPE tissue sections 
5 μm in thickness were enriched by manual microdissec-
tion. Then, RNA was extracted and purified from the FFPE 
tissue sections using the Qiagen RNeasy FFPE kit (Qiagen 
GmbH, Hilden, Germany) as described by the manufac-
turer. RNA integrity was assessed spectrophotometrically 
using a NanoDrop ND-1000 spectrophotometer (NanoDrop 
Technologies, Wilmington, DE; A260/A230 ratio was more 
than 1.7, and the A260/A280 ratio was greater than 1.8). Total 
RNA was converted into cDNA using the RT2 First Strand Kit 
(Qiagen GmbH) for each sample.
ECM and CAM mRNA Expression by RT2  
Profiler™ PCR Arrays
cDNA for each sample was added to the RT2 SYBR 
Green qPCR Master Mix on PHAS-013 Array (Qiagen 
GmbH), according to the manufacturer’s protocol. This 
array profiles genes involved in ECM structure and remod-
eling, defining connective tissue, cell adhesion, transmem-
brane inhibitors, BM construction, and collagen proteins 
(Table 1). Each 96-well plate contains 84 pathway-specific 
genes of interest, five housekeeping genes (HKGs) used for 
normalization of data, three reverse transcription controls, 
a genomic DNA contamination control, and three positive 
PCR controls.
To analyze the expression data, we used the inte-
grated Web-based software package (http://pcrdataanalysis.
sabiosciences.com/pcr/arrayanalysis.php; Qiagen GmbH). 
Quantitative analysis was based on the ΔΔC
t
 method, with 
normalization of the raw data to one of the HKGs. The Web 
portal automatically performs all ΔΔC
t
-based fold-change cal-
culations from the uploaded raw threshold cycle (Ct) data. The 
fold-change was calculated as the normalized gene expression 
in MPM samples divided by the normalized gene expression 
in MH samples (2(−ΔΔCt)). If this value was greater than 4, the 
result would be considered as a fold up-regulation; however, 
if the fold-change was less than −4, the result would be con-
sidered as a fold down-regulation; the fold-change value of 
4 was chosen to maximize difference in expression between 
MH and MPM.
Immunohistochemistry
Immunohistochemical analysis was performed on 3-μm 
thick tissue sections from the most representative FFPE tissue 
specimen obtained from each of the 26 patients with epitheli-
oid MPM and of the 26 patients with MH.
Immunoreaction was displayed using the avidin–bio-
tin–peroxidase complex method. Peroxidase activity was 
visualized with diaminobenzidine. Counterstaining was per-
formed with hematoxylin. The negative controls were car-
ried out by omitting the primary antibodies. Immunostaining 
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was performed using a Benchmark immunostainer (Ventana, 
Tucson, AZ).
We aimed to identify several molecules, among those 
statistically significant altered (p < 0.01) and in which the 
differential mRNA expression was higher in MPM and MH 
by PCR array, which could be further investigated as putative 
biomarkers of mesothelial carcinogenesis.
For MMP7 and MMP14 immunohistochemical stain-
ing, sections were incubated with a mouse monoclonal anti-
body (clone ID2; Abcam, Cambridge, United Kingdom) used 
at a 1:200 dilution and with a rabbit monoclonal antibody 
(Abcam) used at a 1:200 dilution. Immunostaining for MMP7 
and MMP14 was always cytoplasmic.
For CD44 immunohistochemical staining, sections 
were incubated with a mouse monoclonal antibody (clone 
F10-44-2, diluted 1:100; Abcam). Evaluation of CD44 expres-
sion was based exclusively on membrane staining, although 
cytoplasmic reactivity was also noted.
For integrin, alpha3 (ITGA3) expression, the sections 
were incubated with a mouse monoclonal antibody (clone F35 
177-1; Abcam) used at a 1:100 dilution, and immunohisto-
chemical staining was mainly located in the cytoplasm and 
cell membrane.
In all cases, two pathologists (GA and AP), blinded to 
the PCR array results, evaluated and graded the immunohis-
tochemical staining by scanning the entire section and scor-
ing the percentage of positive tumor cells and their staining 
intensity separately in high-power fields (10× and 20×), using 
previously described scoring system.18,19
Immunostaining was heterogeneous so all cases were 
analyzed using a semiquantitative histologic scoring (H score) 
method. Briefly, immunostaining intensity of each case was 
scored as follows: 0, none; 1, weak; 2, moderate; and 3, 
intense. In addition, the percentage of positive neoplastic cells 
was evaluated. For each case, a value designated H score was 
obtained by multiplying each intensity with the corresponding 
percentage of positive cells, thereby obtaining a final resulting 
score value (possible range, 0–300).
Statistical Analysis
For the purpose of this study, we performed univari-
ate analyses. In the first instance, we used a nonparametric 
Student’s t test to investigate the differences in mRNA gene 
expression between MPM and MH. A p value below 0.01 was 
considered significant. In a second step, we proceeded with 
χ2 tests to validate the differential expression of coded pro-
teins. The subjects were divided into low- and high-expres-
sion groups according to the median H score values (140 for 
ITGA3, 160 for MMP14, 145 for MMP7, and 150 for CD44). 
Statistical p values less than 0.05 were considered significant.
RESULTS
Analysis of Gene Expression Profiles 
by PCR Array
Because of genomic DNA contamination, three samples 
(2 MPM and 1 MH) were classified as inadequate for expres-
sion analysis. Therefore, the PCR array study group was com-
posed of 13 MPMs and nine MHs.
In our current analysis, only four HKGs were used 
for normalization, namely hypoxanthine phosphoribosyl-
transferase1 (HPRT1), ribosomal protein L13a (RPL13A), 
beta-2-microglobulin (B2M), and beta-actin (ACTB). 
Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was 
not included because it was the gene with the most fluctuation 
in expression in our samples.
Of the 84 cancer pathway–focused genes in this array, 
25 genes demonstrated at least a fourfold expression differ-
ence between the MH group and the mesothelioma group. 
Specifically, 12 genes were up-regulated in MPM compared 
with MH, whereas 13 genes seemed to be down-regulated 
in mesothelioma samples. Furthermore, eight genes were 
statistically significantly altered: COL16A1 (40.6851-fold; 
p = 0.0024), ITGB4 (9.755-fold; p = 0.0085), ITGA3 (9.39-fold; 
p = 0.00037), and MMP14 (7.61-fold; p = 0.00069) were 
up-regulated, whereas CD44 (−5.3927-fold; p = 0.000238), 
ITGAM, (−7.0665-fold; p = 0.00004), MMP10 (−11.779-fold; 
TABLE 1.  Functional Gene Grouping
Cell adhesion molecules
  Transmembrane molecules: CD44, CDH1, HAS1, ICAM1, ITGA1, ITGA2, ITGA3, ITGA4, ITGA5, ITGA6, ITGA7, ITGA8, ITGAL, ITGAM, ITGAV,  
  ITGB1, ITGB2, ITGB3, ITGB4, ITGB5, MMP14, MMP15, MMP16, NCAM1, PECAM1, SELE, SELL, SELP, SGCE, SPG7, VCAM1
Cell–cell adhesion: CD44, CDH1, COL11A1, COL14A1, COL6A2, CTNND1, ICAM1, ITGA8, VCAM1
Cell–matrix adhesion: ADAMTS13, CD44, ITGA1, ITGA2, ITGA3, ITGA4, ITGA5, ITGA6, ITGA7, ITGA8, ITGAL, ITGAM, ITGAV, ITGB1, ITGB2,  
  ITGB3, ITGB4, ITGB5, SGCE, SPP1, THBS3
Other adhesion molecules: CNTN1, COL12A1, COL15A1, COL16A1, COL5A1, COL6A1, COL7A1, COL8A1, VCAN, CTGF, CTNNA1, CTNNB1, 
CTNND2, FN1, KAL1, LAMA1, LAMA2, LAMA3, LAMB1, LAMB3, LAMC1, THBS1, THBS2, CLEC3B, TNC, VTN
Extracellular matrix proteins
  Basement membrane constituents: COL4A2, COL7A1, LAMA1, LAMA2, LAMA3, LAMB1, LAMB3, LAMC1, SPARC
  Collagens and ECM structural constituents: COL11A1, COL12A1, COL14A1, COL15A1, COL16A1, COL1A1, COL4A2, COL5A1, COL6A1, COL6A2,  
  COL7A1, COL8A1, FN1, KAL1
  ECM proteases: ADAMTS1, ADAMTS13, ADAMTS8, MMP1, MMP10, MMP11, MMP12, MMP13, MMP14, MMP15, MMP16, MMP2, MMP3, MMP7,  
  MMP8, MMP9, SPG7, TIMP1
  ECM protease inhibitors: COL7A1, KAL1, THBS1, TIMP1, TIMP2, TIMP3
  Other ECM molecules: VCAN, CTGF, ECM1, HAS1, SPP1, TGFBI, THBS2, THBS3, CLEC3B, TNC, VTN
ECM, extracellular matrix.
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p = 0.004162), and MMP7 (−6.1481-fold; p = 0.005387) were 
down-regulated (Tables 2 and 3; Fig. 1).
Confirmation of Differential Gene Expression 
Detected by Array: Immunohistochemical 
Expression of MMP7, MMP14, CD44, 
and ITGA3 in MPM and MH
To verify the results of the array experiments and to better 
define the possible role of MMP7, MMP14, CD44, and ITGA3 
in MPM and MH, we decided to investigate their expression 
by immunohistochemistry in a group of 52 well-characterized 
MPM and MH specimens, including the 25  samples analyzed 
using RT-PCR arrays. Table 4 shows a summary of the results 
from the immunohistochemical analyses.
Immunohistochemical studies of MPM and MH tissue 
specimens confirmed the differences detected by array analy-
sis regarding MMP14, CD44, and ITGA3 expression.
Immunohistochemistry revealed higher MMP14 and 
ITGA3 expression in epithelioid mesothelioma compared with 
MH (p = 0.000002 and p = 0.000002, respectively; Table 4; 
Fig. 2). Evaluation of the CD44 expression revealed a signifi-
cant difference (p = 0.0013) between MPM and MH. According 
to the H scoring system, CD44 expression was low or negative 
in most (57.7%) mesothelioma samples but only in 11.5% of 
MH samples (Table 4; Fig. 2). Regarding MMP7 staining, we 
did not observe different expression between MH and MPM 
(p = 0.8864; Table 4).
DISCUSSION
The separation of benign from malignant mesothelial 
proliferations is even more crucial to patient management 
than determining whether a process is mesothelial in origin, 
and invasion is still the most reliable indicator of malignancy 
in this setting.6–11
The invasion of cancer cells is a complex process that 
involves several molecules, such as MMPs20–27 and CAMs.14–16 
The first goal of this work was to identify specific gene expres-
sion changes in cancerous and reactive mesothelial cells. The 
RT2 Profiler PCR Arrays are designed to determine the expres-
sion profile of a specific panel of genes. Using array technology, 
we analyzed the expression of 84 genes involved in cell–cell 
TABLE 2.  Up-Regulated Genes in MPM Compared withThose in MH
Gene Symbol Description Fold Regulation p
CDH1 Cadherin 1, type 1, E-cadherin (epithelial) 11.9033 0.02715
COL16A1 Collagen, type XVI, alpha 1 40.6851 0.002421
COL4A2 Collagen, type IV, alpha 2 4.891 0.157201
CTNNA1 Catenin (cadherin-associated protein), alpha 1, 102 kDa 4.608 0.058048
ITGA3 Integrin, alpha 3 (antigen CD49C, alpha 3 subunit of VLA-3 receptor) 9.3966 0.000378
ITGB4 Integrin, beta 4 9.755 0.008579
LAMA3 Laminin, alpha 3 4.6622 0.013096
LAMC1 Laminin, gamma 1 (formerly LAMB2) 4.1064 0.187184
MMP14 Matrix metalloproteinase 14 (membrane-inserted) 7.6143 0.000694
MMP3 Matrix metalloproteinase 3 (stromelysin 1, progelatinase) 5.8349 0.273049
THBS2 Thrombospondin 2 6.5985 0.244294
MPM, malignant pleural mesothelioma; MH, mesothelial hyperplasia; VLA-3, very late antigen-3.
TABLE 3.  Down-Regulated Genes in MPM Compared with Those in MH
Gene Symbol Description Fold Regulation p
ADAMTS1 ADAM metalloproteinase with thrombospondin type 1 motif, 1 −5.6406 0.151501
ADAMTS8 ADAM metalloproteinase with thrombospondin type 1 motif, 8 −4.8457 0.020408
CD44 CD44 molecule (Indian blood group) −5.3927 0.000238
ITGA5 Integrin, alpha 5 (fibronectin receptor, alpha polypeptide) −5.4323 0.229302
ITGA7 Integrin, alpha 7 −5.6675 0.069381
ITGAM Integrin, alpha M (complement component 3 receptor 3 subunit) −7.0665 0.00004
MMP1 Matrix metalloproteinase 1 (interstitial collagenase) −7.008 0.085905
MMP10 Matrix metalloproteinase 10 (stromelysin 2) −11.779 0.004162
MMP12 Matrix metalloproteinase 12 (macrophage elastase) −6.5516 0.070498
MMP7 Matrix metalloproteinase 7 (matrilysin, uterine) −6.1481 0.005387
MMP9 Matrix metalloproteinase 9 (gelatinase B, 92 kDa gelatinase, 92 kDa type IV collagenase) −14.777 0.140619
SELE Selectin E −4.7999 0.217184
TIMP3 TIMP metallopeptidase inhibitor 3 −5.5575 0.340457
MPM, malignant pleural mesothelioma; MH, mesothelial hyperplasia; TIMP, tissue inhibitor of metalloproteinase-3.
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adhesion, cell–matrix interactions, and ECM remodeling in 15 
epithelioid MPM samples and 10 MH samples to understand 
the molecular basis of mesothelioma development and pro-
gression. Three samples (2 MPM and 1 MH) were classified 
as inadequate for mRNA analysis. Therefore, the PCR array 
study group was composed of 13 MPM and nine MH. In these 
specific pathways of genes, we identified 25 genes that demon-
strated different expression between MH tissue and epithelioid 
mesothelioma tissue. In particular, up-regulation was observed 
in 12 genes (CDH1, COL16A1, COL4A2, CTNNA1, ITGA3, 
ITGB4, LAMA3, LAMC1, MMP14, MMP3, THBS2) in 
MPM compared with MH, whereas 13 genes (ADAMTS1, 
ADAMTS8, CD44, ITGA5, ITGA7, ITGAM, MMP1, 
MMP10, MMP12, MMP7, MMP9, SELE, TIMP3) seemed 
to be down-regulated in the tumor samples. Moreover, among 
the genes differentially expressed in MPM and MH by PCR 
array, we observed some interesting genes that were statisti-
cally significant altered (COL16A1, ITGB4, ITGA3, MMP14, 
CD44, ITGAM, MMP10, and MMP7). These observations 
highlighted the important role of the pathways analyzed in the 
present study in mesothelial carcinogenesis. Indeed, our data 
confirmed some previously described differences in expression 
patterns of molecules involved in cytoskeletal reorganization, 
cell–cell adhesion and cell–matrix interactions.12,25,28–30
The second goal of the present study was to confirm 
the results of genomic array analysis by evaluation of protein 
expression. To this aim, we identified some molecules, among 
those statistically significant altered in MPM and MH, which 
could be further investigated as putative biomarkers of meso-
thelial carcinogenesis. Indeed, these molecules are membrane 
proteins that are implicated in cancer invasion/metastasis 
and in initiation or growth in several cancer models, such as 
MMP7,12,31–34 ITGA3,15,16 CD44,35–37 and MMP14.38 However, 
FIGURE 1.  Volcano plot showing gene 
expression differences between MPM and 
MH samples. Each spot represents a single 
gene. Left vertical axis indicates fourfold 
lower expression in MPM versus MH 
(green spots); central vertical axis indicates 
no difference in gene expression; right ver-
tical axis indicates fourfold higher expres-
sion in MPM versus MH (red spots). The 
blue horizontal line indicates the desired 
threshold for the t test p value = 0.01. 
Statistically significant up- and down-
regulated genes are indicated by gene 
symbol, COL16A1 (Collagen, type XVI, 
alpha 1), ITGA3, ITGB4, MMP14, CD44, 
ITGAM, MMP10, and MMP7, respectively. 
MPM, malignant pleural mesothelioma; 
MH, mesothelial hyperplasia; ITGA3, integ-
rin, alpha 3; ITGB4, integrin, beta 4; MMP, 
matrix metalloproteinase; ITGAM, integrin, 
alpha M.
TABLE 4.  Association between Immunohistochemical 
Characteristics and Histology of the Patients Enrolled in 
the Study
Immmunoistochemical 
Characteristics
Epithelioid  
Mesothelioma 
(N = 26)
n Cases (%)
Mesothelial  
Hyperplasia 
(N = 26)
n cases (%) p
MMP7 H score
  Low 13 (50.0) 13 (50.0) 0.8864
  High 13 (50.0) 13 (50.0)
MMP14 H score
  Low 6 (23.1) 23 (88.5) 0.000002
  High 20 (76.9) 3 (11.5)
CD44 H score
  Low 20 (76.9) 8 (30.8) 0.0013
  High 6 (23.1) 18 (69.2)
ITGA3 H score
  Low 6 (23.1) 23 (88.5) 0.000002
  High 20 (76.9) 3 (11.5)
MMP7, matrix metalloproteinase 7; MMP14, matrix metalloproteinase 14; ITGA3, 
integrin, alpha 3.
Bold indicates statistical significance (P < 0.05).
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the role of these proteins in tumor invasion and progression in 
mesothelioma has not been investigated. In particular, immu-
nohistochemical expression of MMP7, MMP14, and ITGA3 
has not been evaluated in mesothelioma compared with MH. 
On the contrary, CD44 was extensively investigated as positive 
diagnostic mesothelial marker, but for the first time we high-
lighted by PCR array a different expression in MPM and MH 
and this preliminary observation deserves further investigation. 
Therefore, we investigated the immunohistochemical expres-
sion of the above molecules in 26 epithelioid mesothelioma 
and 26 MH specimens. Immunohistochemical studies of MPM 
and MH tissue specimens confirmed the differences detected 
by array analysis in MMP14, CD44, and ITGA3 expression.
In our study, we observed significantly higher MMP14 
and ITGA3 immunohistochemical expression in epithelioid 
mesothelioma samples compared with MH samples. The 
expression of MMP14 in MPM has been analyzed in only one 
study.25 The authors showed up-regulation of MMP14 in meso-
thelioma compared with normal pleura and MMP14 immuno-
histochemical expression in all mesothelioma samples they 
analyzed. Interestingly, they founded that high immunohisto-
chemical expression of MMP14 was significantly correlated 
with poor survival in mesothelioma. These findings and our 
observations strongly suggest that MMP14 plays a key role 
in tumor progression in MPM and that MMP14 may be a bio-
marker for MPM.
As regards ITGA3, Koukoulis et al.39 showed that it is 
expressed in mesothelioma and that its expression was cor-
related with an epithelial phenotype. Another study revealed 
ITGA3 up-regulation in MPM compared with normal pleural 
tissue by microarray analysis.28 To the best of our knowledge, 
our study was the first to investigate ITGA3 immunohisto-
chemical expression in MH in comparison with mesothe-
lioma, showing a lower expression in benign mesothelioma 
proliferation and supporting the hypothesis of a role of ITGA3 
in mesothelioma oncogenesis.
Our data also showed CD44 expression in mesothe-
lial proliferations, although the expression was lower in the 
malignant samples. This observation confirmed a possible 
use of CD44 as a positive mesothelial marker that could 
be useful in the differential diagnosis of pleural neoplastic 
proliferations.
Furthermore, we observed down-regulation of mRNA 
MMP7 in epithelioid mesothelioma samples compared with 
MH samples, but this result was not confirmed by immunohis-
tochemistry. Therefore, further studies are necessary to sup-
port a possible role of MMP7 in mesothelial carcinogenesis.
In conclusion, we demonstrated that patients with 
MPM had significantly higher MMP14 and ITGA3 expres-
sion and lower CD44 expression compared with patients with 
MH, suggesting that these factors could be biomarkers of 
MPM. Additional study of these proteins may be important 
FIGURE 2.  Immunohistochemical staining. 
A, Epithelioid malignant mesothelioma with strong 
cytoplasmic staining for MMP14. B, Reactive 
mesothelial hyperplasia with negative staining for 
MMP14. C, An example of low CD44 expression 
in an epithelioid mesothelioma. D, Reactive meso-
thelial hyperplasia with strong membrane staining 
for CD44. E, Epithelioid mesothelioma with high 
ITGA3 expression. F, An example of reactive meso-
thelial hyperplasia with negative ITGA3 expression. 
Original magnification, ×100.
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to improve our understanding of the pathogenesis of meso-
thelioma and could represent the bases for further studies to 
improve diagnostic methods and treatments.
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